J. Goldman & CO LP Exelixis, Inc. Transaction History
J. Goldman & CO LP
- $3.21 Billion
- Q3 2024
A detailed history of J. Goldman & CO LP transactions in Exelixis, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 27,000 shares of EXEL stock, worth $977,400. This represents 0.02% of its overall portfolio holdings.
Number of Shares
27,000Holding current value
$977,400% of portfolio
0.02%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding EXEL
# of Institutions
507Shares Held
243MCall Options Held
2.54MPut Options Held
2.29M-
Black Rock Inc. New York, NY33.5MShares$1.21 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.3MShares$1.06 Billion0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA25.4MShares$920 Million3.31% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.4MShares$556 Million0.63% of portfolio
-
State Street Corp Boston, MA11.4MShares$414 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11.7B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...